Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines

Journal of the American Academy of Dermatology

Volumn 51, Issue 1, 2004, Pages 52-61

  Grimes, Pearl E ^a,b   Morris, Robert ^a   Avaniss Aghajani, Erik ^a   Soriano, Teresa ^a   Meraz, Maria ^a   Metzger, Allan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPIGMENTATION; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; EVALUATION; FACE; FEMALE; GENE EXPRESSION; HUMAN; MALE; NECK; OINTMENT; PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SKIN; SKIN BIOPSY; SKIN CELL; SKIN IRRITATION; SKIN PIGMENTATION; STATISTICAL SIGNIFICANCE; SUN EXPOSURE; SYMPTOM; VITILIGO; XEROSIS;

EID: 3042778222     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.12.031     Document Type: Article

References (51)

1. Grimes P.E. XV Disorders of pigmentation. Dale D.C., Federman D.D. 2 Dermatology. WebMD Scientific American (r) Medicine. 2003;526-534 WebMD Inc. New York
2. Bystryn J.-C. Immune mechanisms in vitiligo. Clin Dermatol. 15:1997;853-861
3. Nordlund J.J., Majumder P.P. Recent investigations on vitiligo vulgaris. Dermatol Clin. 15:1997;69-78
4. Lerner A.B. On the etiology of vitiligo and gray hair. Am J Med. 51:1971;141-147
5. Al'Abadie M.S., Senior H.J., Bleehen S.S., Gawkrodger D.J. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 131:1994;160-165
6. Bystryn J.-C. Serum antibodies in vitiligo patients. Clin Dermatol. 7:1989;136-145
7. Castanet J., Ortonne J.P. Pathophysiology of vitiligo. Clin Dermatol. 15:1997;845-851
8. Grimes P.E., Wojdani A., Loeb L.J., Loeb L.J., Franco R., Kelly A.P. The effects of isoprinosine treatment on repigmentation and immunologic aberrations in vitiligo. [abstract] J Invest Dermatol. 98:1992;534
9. Ongenae K., Van Geel N., Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16:2003;90-100
10. Yu H.S., Chang K.L., Yu C.L., Li H.F., Wu M.T., Wu C.S., et al. Alterations in IL-6, IL-8, GM-CSF, TNF-α, and IFN-γ release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol. 108:1997;527-529
11. Honda Y., Okubo Y., Koga M. Relationship between levels of soluble interleukin-2 receptors and the types of activity of vitiligo. J Dermatol. 24:1997;561-563
12. Caixia T., Hongwen F., Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci. 21:1999;59-62
13. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I., Fabiani M., et al. New insights into the pathogenesis of vitiligo Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15:2002;87-92
14. Pasricha J.S., Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol. 33:1994;584-587
15. Mohammad A. Vitiligo repigmentation with Anapsos (Polypodium leucotomos). Int J Dermatol. 28:1989;479
16. Nihei Y., Nishibu A., Kaneko F. Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment. J Dermatol. 25:1998;250-255
17. Grimes P.E., Soriano T., Dytoc M. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 47:2002;789-791
18. Tanghetti E.A. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo results of a prospective patient series. Cutis. 71:2003;158-162
19. Lepe V., Moncada B., Castanedo-Cazares J.P., Torres-Alvarez M.B., Ortiz C.A., Torres-Rubalcava A.B. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 139:2003;651-654
20. Castanedo-Cazares J.P., Lepe V., Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed. 19:2003;35-36
21. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today. 13:1992;136-142
22. Grimes P.E. Vitiligo an overview of therapeutic approaches. Dermatol Clin. 11:1993;325-338
23. Grimes P.E. Therapeutic trends for the treatment of vitiligo. Cosmetic Dermatol. 15:2002;21-25
24. Kang S., Lucky A.W., Pariser D., Lawrence I., Hanifin J.M., Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 44:2001;S58-S64
25. Paller A., Eichenfield L.F., Leung D.Y.M., Stewart D., Appell M., Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 44:2001;S47-S57
26. Soter N.A., Fleischer A.B. Jr., Webster G.F., Monroe E., Lawrence I., Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 44:(Suppl):2001;S39-S46
27. Reitamo S., Rissanen J., Remitz A., Granlund H., Erkko P., Elg P., et al. Tacrolimus ointment does not ancect collagen synthesis results of a single-center randomized trial. J Invest Dermatol. 111:1998;396-398
28. Paller A.S., Caro I., Rico M.J., the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment monotherapy in atopic dermatitis patients: open-label study results. Ann Dermatol Venereol. 129:(Suppl 1):2002;S247
29. Koo J.Y.M., Prose N., Fleischer A., Rico M.J., Tacrolimus Ointment Study Group. Safety and efficacy of tacrolimus ointment monotherapy in over 7900 atopic dermatitis patients: results of an open-label study. Ann Dermatol Venereol. 129:(Suppl 1):2002;S415
30. Quevedo W.C. Jr., Szabo G., Virks J., Sinesi S.J. Melanocyte populations in UV-irradiated human skin. J Invest Dermatol. 45:1965;295-298
31. Rosdahl I.K., Szabo G. Mitotic activity of epidermal melanocytes in UV-irradiated mouse skin. J Invest Dermatol. 70:1978;143-148
32. Jimbow K., Uesugi T. New melanogenesis and photobiological processes in activation and proliferation of precursor melanocytes after UV-exposure ultrastructural differentiation of precursor melanocytes from Langerhans cells. J Invest Dermatol. 78:1982;108-115
33. Erickson K.L., Montagna W. The induction of melanogenesis by ultraviolet light in the pigmentary system of Rhesus monkeys. J Invest Dermatol. 65:1975;279-284
34. Friedmann P.S., Gilchrest B.A. Ultraviolet radiation directly induces pigment production by cultured human melanocytes. J Cell Physiol. 133:1987;88-94
35. Fitzpatrick T.B., Szabo G. The melanocyte cytology and cytochemistry. J Invest Dermatol. 32:1959;197-209
36. Ortonne J.P., Schmitt D., Thivolet J. PUVA-induced repigmentation of vitiligo scanning electron microscopy of hair follicles. J Invest Dermatol. 74:1980;40-42
37. Cui J., Shen L.Y., Wang G.C. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol. 97:1991;410-416
38. Hoover R., Fraumeni J.F. Jr. Risk of cancer in renal transplant recipients. Lancet. 2:1973;55-57
39. Tremblay F., Fernandes M., Habbab F., deB Edwardes M.D., Loertscher R., Meterissian S. Malignancy after renal transplantation incidence and role of type of immunosuppression. Ann Surg Oncol. 9:2002;785-788
40. Woodle E.S., Thistlethwaite J.R., Gordon J.H., Laskow D., Deierhoi M.H., Burdick J., et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue, Study Group. Transplantation. 62:1996;594-599
41. Protopic (tacrolimus) ointment full prescribing information. 2000;Fujisawa Healthcare, Inc. Deerfield (IL)
42. Swope V.B., Abdel-Malek Z., Kassem L.M., Nordlund J.J. Interleukins 1α and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 96:1991;180-185
43. Yohn J.J., Critelli M., Lyons M.B., Norris D.A. Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol. 90:1990;233-237
44. Morelli J.G., Norris D.A. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol. 100:(Suppl): 1993;191S-195S
45. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor biology, function, and clinical application. Ann Intern Med. 13:1990;619-627
46. Le Poole I.C., Das P.K., van den Wijingaard R.M., Bos J.D., Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 2:1993;145-153
47. Lawrence I.D. Tacrolimus (FK506) experience in dermatology. Dermatol Ther. 5:1988;74-84
48. Leung D.Y.M. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 104:1999;S99-S108
49. Halder R.M., Walters C.S., Johnson B.A., Chakrabarti S.G., Kenney J.A. Jr. Abberations in T lymphocytes and natural killer cells in vitiligo a flow cytometric study. J Am Acad Dermatol. 14:1986;733-737
50. Abdel-Naser M.B., Ludwig W.D., Gollnick H., Orfanos C.E. Nonsegmental vitiligo decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol. 31:1992;321-326
51. Grimes P.E., Sevall J.S., Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol. 35:1996;21-26